Labiotech.eu

News and Trends 7 Jul 2015

Novo Nordisk abandons Zosano’s drug delivery technology for diabetes treatment

Novo Nordisk cancels its collaboration deal with Zosano Pharma. The diabetes drug semaglutine won’t be delivered with the microneedle patch technology, developed from the latter. Zosano’s patch technology uses thin titanium microprojections to deliver drugs that cannot permeate the outer layer of the skin. According to Zosano, the system was tested on 400 patients in […]

July 7, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 7 Jul 2015

DIY-Morphine is around the corner with recent Discoveries in Poppies

Bioproduction of future painkillers such as morphine could become a reality. Researchers from the University of York and GlaxoSmithKline Australia made crucial genetic discoveries in the morphinan synthesis pathway, which will allow its production in microbial systems or in genetically selected plant breeds. Opioid alkaloids have been used as painkillers since the dawn of time. The opium latex is […]

July 7, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 7 Jul 2015

Microalgae on Your Plate Thanks to Algama

Nine billion people will have to be fed by 2050! Amongst the considered solutions, microalgae could be a real game-changer. Algama, a young French startup is in the starting-block, with already two products just about to go on the market. Behind Algama there is a friendship story, shared by the three co-founders, Alvyn, Gaëtan and Mathieu. […]

July 7, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 6 Jul 2015

Sartorius Stedim Strengthens its Leadership in Biologics Manufacturing with Cellca’s Acquisition

Sartorius Stedim Biotech, a leading international supplier for the pharma and biotech industries, acquired the German-based Cellca last Wednesday. With this acquisition, Sartorius is strengthening its leading position as a biologics manufacturer. Last year, we visited Cellca during our first biotech Tour in Germany. The company is offering cell line and process development for large-scale protein production […]

July 6, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 6 Jul 2015

ElsaLys Biotech grabs MABLife’s dual-acting antibody to treat cancer

French ElsaLys Biotech just acquired MABLife’s anti-CD160 antibody. Originally developed for the treatment of vascular eye diseases, the antibody also has the potential to be applied for tumor therapy. It inhibits vascular proliferation and modulates the immune system. To proliferate and migrate through the body, tumors rely on oxygen and nutrients supplies. Cancer cells initiate […]

July 6, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 6 Jul 2015

Kiadis launches its Cell-based Immunotherapies on European stock markets

Kiadis Pharma has launched an IPO on Euronext Amsterdam and Euronext Brussels with the aim of raising €32.7M. The company will invest the money in two cell-based immunotherapies for blood cancer and inherited blood disorders. Kiadis has filed for an Initial Public Offering on the Dutch and Belgian exchange markets. The money raised on the […]

July 6, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 6 Jul 2015

After selling its company to Gilead, Martin Bonde joins Norwegian Vaccibody as CEO

Two weeks ago, I travelled through Denmark to interview 15 CEOs to film its biotech industry, Labiotech Tour Denmark. Amongst them was Martin Bonde, CEO of Dansk Biotech and former CEO of Epitherapeutics which was sold at €60M to Gilead (the 2nd largest Biotech in the world). I just read he is switching to Vaccibody the Norwegian Biotech and […]

July 6, 2015 - 1 minutemin - By Philip Hemme

News and Trends 5 Jul 2015

CEVEC and Biotest to ease hemophilia patients’ lifes

A German collaboration seeks to treat the symptoms of hemophilia in patients suffering from the later. CEVEC and Biotest will join forces to produce and commercialize molecules using CEVEC’s expression platform. Biotest develops immunoglobulins, coagulation factors and albumins, based on human blood plasma, used for diseases of the immune and hematopoietic system. This makes it […]

July 5, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 3 Jul 2015

Lilly Cooperates with Immunocore to Fight Skin Cancer

Eli Lilly expands its portfolio in immune-oncology therapies. This time, Immunocore‘s lead T cell receptor-based drug, IMCgp100 is tested in combination with Lilly’s kinase inhibitors galunisertib and merestinib. This second collaboration between these two companies aims to increase drug efficacy against melanoma cancer. Melanomas are rare forms of skin cancer, that have a high potential […]

July 3, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 3 Jul 2015

Nobel Prize’s company start gathering robust clinical data in two phases II

Cell Therapy’s Tendoncel, a topical gel for the treatment of severe tendon injuries, has successfully completed its phase II. The optimistic results from the clinical trial add to those of the company’s leading product, released last week. The UK company has finally started to collect strong clinical data to support its approach. Cell Therapy Limited […]

July 3, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 3 Jul 2015

Yes! Humanity can finally produce Oxygen!

Julian Melchiorri, a student of the Royal College of Art of London is making quite of a buzz outside of Scientists frontiers with his Silk Leaf. A revolutionary material capable of producing O2 from CO2 designed on biomimicry principle. Info or Intox? We’ll let you make your own mind up on the question! For a few years now, […]

July 3, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 2 Jul 2015

Nanobiotix got the all-clear for its new Phase I/II clinical trial

The French National Agency for Medicines and Health Products gave Nanobiotix the green light to start a Phase I/II trial in two new cancer populations for its lead product, NBTXR3. This could lead to an increase in the commercial potential of this promising French Biotech. Nanobiotix is a great French Biotech company, which you can […]

July 2, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Novo Nordisk abandons Zosano’s drug delivery technology for diabetes treatment

DIY-Morphine is around the corner with recent Discoveries in Poppies

Microalgae on Your Plate Thanks to Algama

Sartorius Stedim Strengthens its Leadership in Biologics Manufacturing with Cellca’s Acquisition

ElsaLys Biotech grabs MABLife’s dual-acting antibody to treat cancer

Kiadis launches its Cell-based Immunotherapies on European stock markets

After selling its company to Gilead, Martin Bonde joins Norwegian Vaccibody as CEO

CEVEC and Biotest to ease hemophilia patients’ lifes

Lilly Cooperates with Immunocore to Fight Skin Cancer

Nobel Prize’s company start gathering robust clinical data in two phases II

Yes! Humanity can finally produce Oxygen!

Nanobiotix got the all-clear for its new Phase I/II clinical trial

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!